transplant rejection

The company's AlloSure Kidney test received coverage, along with its AlloSure Heart test when used with the firm's AlloMap test.

The company reported $53.4 million in total revenues for the quarter and said testing services revenues rose 61 percent year over year.

Thermo Fisher's transplant diagnostics products include antibody detection assays, post-transplant monitoring solutions, HLA typing products, and lab instrumentation.

The company said it provided approximately 21,800 total AlloSure and AlloMap patient results during the quarter.

CareDx hopes the final LCD for AlloSure Heart will lead to an approval of HeartCare, a combination of AlloSure Heart and AlloMap Heart.

The company holds a leading position in reproductive testing and is expected to rapidly grow its oncology business to address a total market of $21 billion.

The viral assay, developed with Sentinel Diagnostics, improves the ability to monitor viral loads in critical organ transplant populations for the clinical management of infection.

The company reported $41.8 million in total revenues for the quarter and said testing services revenues rose 41 percent year over year.

The investment bank said CareDx's products are gaining traction and that the stock is positioned for 20 percent to 30 percent growth over the next few years.

The company, which launched the technology in September 2019, said in its Q4 earnings release that it received high marks from beta testers.